Page 91 - Read Online

Page 707 Sharma et al. Cancer Drug Resist 2023;6:688-708 https://dx.doi.org/10.20517/cdr.2023.82

intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019;25:477-86. DOI PubMed PMC
159. Wang EJ, Chen JS, Jain S, et al. Immunotherapy resistance in glioblastoma. Front Genet 2021;12:750675. DOI PubMed PMC
160. Goswami S, Walle T, Cornish AE, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in
glioblastoma. Nat Med 2020;26:39-46. DOI PubMed PMC
161. von Roemeling CA, Wang Y, Qie Y, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and
adaptive antitumour immunity. Nat Commun 2020;11:1508. DOI PubMed PMC
162. Mathewson ND, Ashenberg O, Tirosh I, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell
analysis. Cell 2021;184:1281-98.e26. DOI PubMed PMC
163. Di W, Fan W, Wu F, et al. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916
samples. Cancer Sci 2022;113:756-69. DOI PubMed PMC
164. Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature
2022;604:563-70. DOI
165. Wang G, Zhang Z, Zhong K, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram
tumor microenvironment in glioblastoma. Mol Ther 2023;31:134-53. DOI PubMed PMC
166. Amoozgar Z, Ren J, Wang N, et al. Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial
cells into quasi-antigen-presenting cells. bioRxiv 2022. DOI
167. Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res
2022;41:35. DOI PubMed PMC
168. Chen C, Jing W, Chen Y, et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity
for postoperative glioblastoma therapy. Sci Transl Med 2022;14:eabn1128. DOI
169. Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat
Biotechnol 2020;38:947-53. DOI PubMed PMC
170. Zhang C, Burger MC, Jennewein L, et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst
2016;108:djv375. DOI
171. Ma R, Lu T, Li Z, et al. An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets
glioblastoma. Cancer Res 2021;81:3635-48. DOI PubMed PMC
172. Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K. NKG2D natural killer cell receptor-a short description and potential clinical
applications. Cells 2021;10:1420. DOI PubMed PMC
173. Zhang C, Röder J, Scherer A, et al. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual
targeting and enhances antitumor activity. J Immunother Cancer 2021;9:e002980. DOI PubMed PMC
174. Sun T, Warrington NM, Luo J, et al. Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J
Clin Invest 2014;124:4123-33. DOI PubMed PMC
175. Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain tumors. Cell Mol Life Sci 2015;72:3323-42.
DOI PubMed PMC
176. Ostrom QT, Kinnersley B, Wrensch MR, et al. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.
31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep 2018;8:7352. DOI
177. Zhang H, Liao J, Zhang X, et al. Sex difference of mutation clonality in diffuse glioma evolution. Neuro Oncol 2019;21:201-13. DOI
PubMed PMC
178. Shireman JM, Ammanuel S, Eickhoff JC, Dey M. Sexual dimorphism of the immune system predicts clinical outcomes in
glioblastoma immunotherapy: a systematic review and meta-analysis. Neurooncol Adv 2022;4:vdac082. DOI PubMed PMC
179. Bayik D, Zhou Y, Park C, et al. Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. Cancer
Discov 2020;10:1210-25. DOI PubMed PMC
180. Sabbagh A, Beccaria K, Ling X, et al. Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to
immunotherapy in preclinical glioma models. Clin Cancer Res 2021;27:4325-37. DOI PubMed PMC
181. Sheybani ND, Witter AR, Garrison WJ, Miller GW, Price RJ, Bullock TNJ. Profiling of the immune landscape in murine
glioblastoma following blood brain/tumor barrier disruption with MR image-guided focused ultrasound. J Neurooncol 2022;156:109-
22. DOI PubMed PMC
182. Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol 2019;141:479-86. DOI PubMed PMC
183. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57. DOI PubMed
184. Zhang C, Feng W, Vodovozova E, et al. Photodynamic opening of the blood-brain barrier to high weight molecules and liposomes
through an optical clearing skull window. Biomed Opt Express 2018;9:4850-62. DOI PubMed PMC
185. Mroz P, Vatansever F, Muchowicz A, Hamblin MR. Photodynamic therapy of murine mastocytoma induces specific immune
responses against the cancer/testis antigen P1A. Cancer Res 2013;73:6462-70. DOI PubMed PMC
186. Sasaki M, Tanaka M, Kojima Y, et al. Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-
programmed death 1 antibody. Mol Ther Oncolytics 2023;28:118-31. DOI PubMed PMC
187. Semyachkina-glushkovskaya O, Khorovodov A, Fedosov I, et al. A novel method to stimulate lymphatic clearance of beta-amyloid
from mouse brain using noninvasive music-induced opening of the blood-brain barrier with EEG markers. Appl Sci 2021;11:10287.
DOI
188. Semyachkina-Glushkovskaya O, Chehonin V, Borisova E, et al. Photodynamic opening of the blood-brain barrier and pathways of